The Food and Drug Administration granted premarket approval to Thermo Fisher Scientifics' lung cancer biomarker sequencing test.
The Oncomine Dx Target Test assesses tumor samples for the presence of biomarkers associated with three drug therapies approved to treat non-small cell lung cancer.
Physicians can use the test to identify the ideal therapy option for each patient, based on his or her own biomarkers.
Thermo Fisher Scientifics will roll out the test to several laboratories across the country, including Burlington N.C.-based LabCorp; Fort Myers, Fla.-based NeoGenomics Laboratories; and Rutherford, N.J.-based Cancer Genetics.
More articles on supply chain:
Viewpoint: 4 insights into postapproval monitoring of medical devices
6 drugmakers in the headlines
Philips acquires noninvasive neurodiagnostics company for $36M